Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……
Obesity Today—March 31, 2026
This week’s Obesity update highlights regulatory progress, advancing late-stage…
Obesity Today—March 24, 2026
This week’s Obesity update highlights regulatory progress, advancing clinical…
Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly
Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly…
Obesity Today—March 17, 2026
This week’s Obesity update highlights regulatory approvals, emerging generic…
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide collaboration
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide…
Obesity Today—March 10, 2026
This week’s Obesity update highlights regulatory approvals, emerging generic…
Obesity Video Recap—March 3, 2026
This biweekly Obesity video recap highlights late-stage combination data,…
AI in Healthcare and Digital Health Today—March 2, 2026
This week’s AI in Healthcare and Digital Health update highlights…
Obesity Today—February 17, 2026
This week's Obesity update highlights late-stage clinical progress, Phase 3…
Lucid Diligence Brief: Moonwalk Biosciences pivots from CRISPR-based epigenetic editing to siRNA obesity therapies
Lucid Diligence Brief: Moonwalk Biosciences pivots from CRISPR-based epigenetic…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…